Study of Multiple Doses of Saxagliptin (BMS-477118)

Phase 2 Completed 423 enrolled AstraZeneca

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.

Timeline

Start: 2003-05
Primary completion: 2004-05
Completion: 2004-05

Publications

Background Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008 May;10(5):376-86. doi: 10.1111/j.1463-1326.2008.00876.x. Epub 2008 Mar 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	2.5 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	5 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	10 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	20 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	40 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	100 mg	Oral

Study of Multiple Doses of Saxagliptin (BMS-477118)

Summary

Timeline

Publications

Drugs

Indications